Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
Date:11/5/2007

alization agreement entered into in June 2006. HGS and Novartis will co-commercialize Albuferon in the United States and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the world and will pay HGS a royalty on those sales. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 million, including $132.5 million received to date.

About Hepatitis C

Hepatitis C is an inflammation of the liver caused by the hepatitis C virus (HCV). An estimated 170 million people worldwide are infected with the virus, including nearly 4 million people in the United States. When detectable levels of HCV persist in the blood for at least six months, a person is diagnosed with chronic hepatitis C. Hepatitis C virus can cause serious liver disease, leading to cirrhosis, primary liver cancer and even death.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancers.

For more information about HGS, please visit the Company's web site at

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... A strategic assessment of the competitive ... highest priority management responsibilities, the task ... profitability. Timely and factual competitive intelligence ...
(Date:12/15/2009)... CLEVELAND, Dec. 15 At today,s regular meeting ... (NYSE: LZ ), the board declared a ... March 10, 2010 to holders of record at the ... About The Lubrizol Corporation ,, The Lubrizol Corporation ... chemical company that produces and supplies technologies that improve ...
(Date:12/15/2009)... Varian Medical Systems (NYSE: VAR ) announced ... of fiscal year 2010 following the close of regular ... release will be followed by a teleconference available to ... news release and a link to the conference call ... www.varian.com/investor . To access the teleconference call ...
Breaking Medicine Technology:Reportlinker Adds Top Ten World's Leading Orthopedics Companies 2Reportlinker Adds Top Ten World's Leading Orthopedics Companies 3Lubrizol Declares Dividend 2Varian Medical Systems Schedules First Quarter FY2010 News Release and Conference Call 2FDA Approves Seasonal Flu Vaccine for 2009 2010 52150 1FDA Approves Seasonal Flu Vaccine for 2009 2010 52150 2FDA Approves Seasonal Flu Vaccine for 2009 2010 52150 3In New York City Trans Fat Ban Is Working 52148 1In New York City Trans Fat Ban Is Working 52148 2In New York City Trans Fat Ban Is Working 52148 3CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 52146 1CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 52146 2CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 52146 3
... Neurogen,Corporation (Nasdaq: NRGN) today announced that data from ... NG2-73, the Company's,lead compound for the treatment of ... 2007 Annual Meeting of the Associated,Professional Sleep Societies ... with NG2-73 in chronic insomnia patients,are currently being ...
... of Patients and Was,Well-Tolerated ,PRINCETON, NJ, Jun 14, ... Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical,company that develops ... completed Phase 2/3 study of liarozole,in lamellar ichthyosis, ... 200,000) which is characterized by a thick,scaling of ...
Other Medicine Technology:Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 4Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 5Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 2Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 3Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 4Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 5
(Date:12/15/2009)... couples of reproductive age were evaluated, Italian study found ... of children born with cystic fibrosis decreases when screening ... increases, a new study finds. , CF neonatal screening ... for many years. Since the 1990s, the area has ... infants born with CF. , Two different CF carrier ...
(Date:12/15/2009)... The American Diabetes Association and the CDC have released some sobering ... the United States. Treadmill desks offer employers an effective means of ... ... AZ (Vocus) December 14, 2009 -- Rates of diabetes are climbing ... in obesity rates. Despite this rise the American Diabetes Association has ...
(Date:12/15/2009)... Dec. 15 4R Systems, Inc., a ... solutions which help retailers significantly increase profits by ... announced today that The Vitamin Shoppe has been ... "4R,s store and DC inventory solutions have helped ... and in-stocks over the last two years," said ...
(Date:12/15/2009)... The new compact LifeSpan TR200 folding treadmill, ... ), was highly praised by treadmill review groups ... The compact TR200 folding treadmill received awards for Best ... $1000. ,, The compact LifeSpan TR200 treadmill is ... spaces. "This category buster is a very compact treadmill ...
(Date:12/15/2009)... links chronic obstructive pulmonary disease, or COPD, with increased ... the body,s immune system. , The University of ... of the immune system,s role in COPD, a serious, ... Americans with wheezing, shortness of breath, chest tightening and ... are to find better ways to detect and treat ...
Breaking Medicine News(10 mins):Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Immune cell activity linked to worsening COPD 2Health News:Immune cell activity linked to worsening COPD 3
... in Europe should be doubled over the next ten ... and to nurture a thriving European medical research industry. ... medical research and improved career paths for medical scientists. ... the European Medical Research Councils (EMRC) White Paper, Present ...
... 14th, VICTORVILLE, Calif., Feb. 5 Dr. Richard ... Victorville Senior,Valentine,s Day Luncheon. They will host this special ... the Victorville Senior Hall., The event is open ... sit down,meal from Carino,s Italian Grill and entertainment by ...
... nonsmokers to report lack of restful slumber, study says , , ... more likely to feel tired when they wake up and ... a new study finds. , This may be because smokers ... disturbances, suggest the study authors, whose report appears in the ...
... out to be a clue leading researchers at Washington ... a new treatment approach for Niemann-Pick disease, a rare, ... defect in Niemann-Pick disease, the researchers suggest that chemical ... cell,s quality control machinery. And they believe the approach ...
... an agreement with an ESA-led consortium to provide ... the premature deaths of hundreds of thousands of ... Environment Agency (EEA) will use a service, which ... from 29 European countries to deliver accurate information ...
... Keystone Human Services (KHS),is pleased to announce ... privately,owned, Pennsylvania based for-profit agency serving individuals ... 35 years. Impact,Systems, Inc., serving Dauphin, Cumberland/Perry, ... an important component of,Keystone,s regional system of ...
Other Medicine News:Health News:Collaboration needed for strengthening medical research in Europe 2Health News:Smokers Sleep Less Soundly 2Health News:Chemical chaperone could open door to treatment of neurological disorder 2Health News:Chemical chaperone could open door to treatment of neurological disorder 3Health News:Satellite data to deliver 'state-of-the-art' air quality information 2Health News:Keystone Human Services Acquires Impact Systems, Inc. 2
Width 3 (76 mm), length 6 3/4 (171 mm). Pattie Tray attaches to long or short arm....
Kit is supplied with four secondary bars. Secondary bars attach to primary bar. Length 12 (305 mm)....
TEW serrated micro-retractor blade set....
Mini-Vise....
Medicine Products: